Shanghai-based cancer drugmaker Abbisko lines up $42M B round as it makes a leap for the clinic
Qiming Ventures is leading a B round for Abbisko Therapeutics, more than doubling the Shanghai-based biotech’s previous haul as it hustles a pair of homegrown …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.